Molecular structure of PD 184,352, CAS Number: 212631-79-3
PD 184,352 (CAS 212631-79-3)
See product citations (34)
Alternate Names:
2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; CI-1040
Application:
PD 184,352 is a MEK inhibitor
CAS Number:
212631-79-3
Purity:
≥95%
Molecular Weight:
478.65
Molecular Formula:
C17H14ClF2IN2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
PD 184,352 is a MEK inhibitor (IC50 = 10-100 nM), a kinase upstream in the mitogen-activated protein kinase pathway (MAPK). Inhibition of MEK leads to a reduction of MAPK activation, suppressing colon tumor proliferation in mice with limited organism toxicity. PD 184,352 is an inhibitor of MEK-1 and MEK-2.
PD 184,352 (CAS 212631-79-3) References
- Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. | Sebolt-Leopold, JS., et al. 1999. Nat Med. 5: 810-6. PMID: 10395327
- Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow. | Steensma, DP., et al. 2003. Haematologica. 88: 1072-4. PMID: 12969818
- The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. | Klein, PJ., et al. 2006. Neoplasia. 8: 1-8. PMID: 16533420
- Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. | VanBrocklin, MW., et al. 2009. Cancer Res. 69: 1985-94. PMID: 19244105
- Regulation of brachyury by fibroblast growth factor receptor 1 in lung cancer. | Hu, Y., et al. 2016. Oncotarget. 7: 87124-87135. PMID: 27893433
- Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. | Scott, AT., et al. 2020. Clin Cancer Res. 26: 2011-2021. PMID: 31937620
- Oncogenic Signaling Alters Cell Shape and Mechanics to Facilitate Cell Division under Confinement. | Matthews, HK., et al. 2020. Dev Cell. 52: 563-573.e3. PMID: 32032547
- Machine Learning Based Network Analysis Determined Clinically Relevant miRNAs in Breast Cancer. | Qiu, M., et al. 2020. Front Genet. 11: 615864. PMID: 33281885
- Transcriptional Regulation of Thrombin-Induced Endothelial VEGF Induction and Proangiogenic Response. | Catar, R., et al. 2021. Cells. 10: PMID: 33920990
- Identification of a Ferroptosis-Related Signature Model Including mRNAs and lncRNAs for Predicting Prognosis and Immune Activity in Hepatocellular Carcinoma. | Chen, ZA., et al. 2021. Front Oncol. 11: 738477. PMID: 34568075
- A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE. | Xia, Z., et al. 2022. J Oncol. 2022: 2704862. PMID: 36213835
- Identifying and validating key genes mediating intracranial aneurysm rupture using weighted correlation network analysis and exploration of personalized treatment. | Wu, J., et al. 2022. Ann Transl Med. 10: 1057. PMID: 36330394
- Inflammation produced by senescent osteocytes mediates age-related bone loss. | Wang, Z., et al. 2023. Front Immunol. 14: 1114006. PMID: 36814916
Inhibitor of:
ARPP-19, Cactin, CKR-7, ERK 4, LOC728102, MANBAL, MAPK15, MEK-1, MEK-2, MEK-5, MEK2, MEK3, Mxi 2, NanogNB, SPRED1, SPRED2, Ste7, T2BP, THAP10, TMEFF1, and WAVE3.Activator of:
AP1GBP1, Cot, DAPL1, FGF-5, H-Ras, PCDHAC1_Pcdhac1, and Ym1.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PD 184,352, 1 mg | sc-202759 | 1 mg | $40.00 | |||
PD 184,352, 5 mg | sc-202759A | 5 mg | $260.00 |